




1A.



1B.



1C.



2


3

der(2)

der(3)



Figure 2

2A.



2C.


2 B.



2

Figure 3

3A. PAX8-PPAR γ STRUCTURE:




PAX8e7-PPAR γ e1: AGA CCT ACC CCG TGG TGG CAG -- AAA TGA CCA TGG TTG ACA CAG

PAX8e8-PPAR γ e1: CGG GCC AGG CCC TCC TCT CAG -- AAA TGA CCA TGG TTG ACA CAG

PAX8e9-PPAR γ e1: CCA TCG CAG GCA TGG TGG CAG -- AAA TGA CCA TGG TTG ACA CAG

3 B. PAX8-PPAR γ mRNA:



3 C. PAX8-PPAR γ PROTEIN:






Figure 4

4A. PAX8-PPAR γ RTPCR:




4B. PAX8-PPAR γ IMMUNOHISTOCHEMISTRY:




4C.

THYROID NEOPLASM	RT-PCR	IMH
Follicular Carcinoma	5/8	7/8
Follicular Adenoma	0/20	0/20
Papillary Carcinoma	0/10	0/10
Multi-nodular Hyperplasia	0/10	0/10

THYROID FOLLICULAR CARCINOMA: t(2;3)(q13;p25)---->PAX8-PPARY



ACUTE PROMYELOCYTIC LEUKEMIA: t(15;17)(q22;q11-21) ---->PML-RAR α



ALVEOLAR RHABDOMYOSARCOMA: t(2;13)(q35;q14) ---->PAX3-FKHR





Figure 5

Figure 6

b A.



b B.

